Incretin-Related Therapies
in Diabetes: Virtual Grand Rounds
Improving Adherence to Therapy
 |
||
|
How to Obtain AMA PRA
|
|
 |
||
Release Date: January 29, 2010
Expiration Date: January 29, 2011
Estimated Time of Completion: 1 hour
Description
The purpose of this activity is to describe approaches for improving patient adherence to treatments for type 2 diabetes.
Objectives
- Outline the relative merits and drawbacks of therapies for patients with type 2 diabetes who are not achieving therapeutic goals with lifestyle interventions and metformin.
- Discuss the importance of including the patient with type 2 diabetes in treatment decisions.
- Describe the role of the multidisciplinary team in improving adherence in patients being treated for type 2 diabetes.
Target Audience
This activity is directed to endocrinologists, primary care physicians, internists and other healthcare professionals who manage and treat patients with type 2 diabetes.
Accreditation
The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The Cleveland Clinic Foundation Center for Continuing Education designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.
Activity Director
Charles Faiman, MD, FRCPC, MACE
Consultant and Past Chairman
Department of Endocrinology, Diabetes and Metabolism
Cleveland Clinic
Cleveland, Ohio
Author / Faculty
Leann Olansky, MD
Staff Physician
Department of Endocrinology, Diabetes and Metabolism
Endocrinology and Metabolism Institute
Cleveland Clinic
Cleveland, Ohio
Faculty Disclosure
In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.
The following faculty has indicated that he may have a relationship which, in the context of his presentation, could be perceived as a potential conflict of interest:
| Leann Olansky, MD | ||
| Teaching and Speaking | Lilly USA, LLC; Merck & Co., Inc.; Takeda Pharmaceuticals North America, Inc. | |
| Board Membership | Takeda Pharmaceuticals North America, Inc. | |
The following faculty has indicated that he has no relationship which, in the context of his presentation, could be perceived as a potential conflict of interest:
Charles Faiman, MD, FRCPC, MACE
The Cleveland Clinic Foundation Center for Continuing Education acknowledges educational grants for partial support of this activity from:
Amylin Pharmaceuticals, Inc. and Lilly USA, LLC;
Boehringer Ingelheim Pharmaceuticals, Inc.;
Bristol-Myers Squibb Company and AstraZeneca Pharmaceuticals LP
This CME activity was produced by the Cleveland Clinic Center for Continuing Education,
Cleveland Clinic Endocrinology & Metabolism Institute and DIME.
